Drugs / Oteracil Porassium
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06992362 | May 2025 → Dec 2026 expected | hepatoid adenocarcinoma | Peking University Cancer Hospital & Institute | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Oteracil Porassium | “Tegafur,Gimeracil and Oteracil Porassium Capsules” NCT06992362 ↗ |
| Route | Oral | “Tegafur,Gimeracil and Oteracil Porassium Capsules (by body surface area: BSA\<1.25m2, 40mg; BSA≥1.25m2, \<1.5m2, 50mg; BSA≥1.5m2,60mg), orally, twice a day” NCT06992362 ↗ |